MaxCyte (MXCT) Corporate presentation summary

Platform and market

• Expert spans DTX, ATX, STX, GTX and VLX, from research-scale to 200B-cell processing; reported transfection efficiency and cell viability each exceed 90%, depending on cell type and molecule.

• Flow electroporation supports closed cGMP workflows, delivery of nucleic acids, gene-editing tools and proteins, and scaling from concept through clinic; IP portfolio includes 200+ granted and 100+ pending patents.

• Ex-vivo market estimates: 124 research programs, 383 preclinical, 249 clinical and 10 commercial; non-viral shares range from 66% in research to 10% in commercial.

• Cell and gene therapy sector: ~2,130 active clinical trials as of Dec 2025, $11.1B raised in 2025 and 50 approved therapies.

Commercial model and partnerships

• Preclinical revenue comes from instrument sales and single-use processing assemblies; clinical and commercial economics add annual license fees, milestones and royalties or sales-based payments.

• SPL portfolio: 28 partners, 16 preclinical programs, 13 clinical programs and 1 commercial program; ~$105M in precommercial milestone potential and >$30M in milestone payments to date.

• CASGEVY received FDA approvals for sickle cell disease in Dec 2023 and transfusion-dependent beta-thalassemia in Jan 2024; European Commission approvals followed in Feb 2024 for both indications.

• Genentech partnership provides portfolio-wide access to GTX and complementary technologies, supporting ex-vivo engineering from discovery through cGMP manufacturing.

• Pipeline waves include 5 candidates with launch potential in 2027–2028, 9 Phase 1 candidates with potential from 2028+, and 16 preclinical candidates with potential from 2032+.

Financial performance and capital

• FY2025 core revenue was $29.6M, down 9% YoY; total revenue was $33.0M, down 15%. 9M 2026 core revenue was $20.9M, down 9%, while total revenue was $27.1M, up 5%.

• 9M 2026 SPL-related revenue was $6.2M, up 115% YoY; GAAP gross margin was 82%, non-GAAP adjusted gross margin 78%, net loss $18.4M and EBITDA loss $19.5M.

• As of Sep 30, 2026, cash, cash equivalents and investments totaled $133M; installed instrument base was 936, and 41% of core revenue came from SPL partners.

• Spending priorities include product development, targeted inorganic investment, alignment of resources to growth areas and lower annual cash burn; stated goal is profitability with existing capital.